IS5865A - Lyfjasamsetningar með stýrða losun sem innihalda CGMP PDE-5 lata - Google Patents

Lyfjasamsetningar með stýrða losun sem innihalda CGMP PDE-5 lata

Info

Publication number
IS5865A
IS5865A IS5865A IS5865A IS5865A IS 5865 A IS5865 A IS 5865A IS 5865 A IS5865 A IS 5865A IS 5865 A IS5865 A IS 5865A IS 5865 A IS5865 A IS 5865A
Authority
IS
Iceland
Prior art keywords
inhibitors
controlled
pharmaceutical compositions
compositions containing
release pharmaceutical
Prior art date
Application number
IS5865A
Other languages
English (en)
Inventor
King Elizabeth
James Macrae Ross
Original Assignee
Pfizer Research And Development Company, N.V./S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS5865(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9823192.1A external-priority patent/GB9823192D0/en
Priority claimed from GBGB9825117.6A external-priority patent/GB9825117D0/en
Priority claimed from GBGB9826392.4A external-priority patent/GB9826392D0/en
Application filed by Pfizer Research And Development Company, N.V./S.A. filed Critical Pfizer Research And Development Company, N.V./S.A.
Publication of IS5865A publication Critical patent/IS5865A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS5865A 1998-10-23 2001-02-27 Lyfjasamsetningar með stýrða losun sem innihalda CGMP PDE-5 lata IS5865A (is)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9823192.1A GB9823192D0 (en) 1998-10-23 1998-10-23 Pharmaceutical formulations
GBGB9825117.6A GB9825117D0 (en) 1998-11-16 1998-11-16 Pharmaceutical formulations
GBGB9826392.4A GB9826392D0 (en) 1998-11-27 1998-11-27 Pharmaceutical formulations
PCT/IB1999/001619 WO2000024383A1 (en) 1998-10-23 1999-10-04 Controlled-release pharmaceutical formulations containing a cgmp pde-5 inhibitor

Publications (1)

Publication Number Publication Date
IS5865A true IS5865A (is) 2001-02-27

Family

ID=27269526

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5865A IS5865A (is) 1998-10-23 2001-02-27 Lyfjasamsetningar með stýrða losun sem innihalda CGMP PDE-5 lata

Country Status (44)

Country Link
US (1) US6964780B1 (is)
EP (1) EP1123088B1 (is)
JP (1) JP2002528408A (is)
KR (1) KR20010075659A (is)
CN (1) CN1324233A (is)
AP (1) AP2001002125A0 (is)
AT (1) ATE340562T1 (is)
AU (1) AU756509B2 (is)
BG (1) BG65323B1 (is)
BR (1) BR9914718A (is)
CA (1) CA2348086C (is)
CO (1) CO5160262A1 (is)
CR (1) CR6326A (is)
CY (1) CY1106239T1 (is)
CZ (1) CZ20011427A3 (is)
DE (1) DE69933383T2 (is)
DK (1) DK1123088T3 (is)
DZ (1) DZ2923A1 (is)
EA (1) EA004068B1 (is)
EE (1) EE200100235A (is)
ES (1) ES2272082T3 (is)
GT (1) GT199900184A (is)
HK (1) HK1041818A1 (is)
HR (1) HRP20010285A2 (is)
HU (1) HUP0104318A3 (is)
ID (1) ID28232A (is)
IL (1) IL141764A (is)
IS (1) IS5865A (is)
MA (1) MA26700A1 (is)
MX (1) MXPA01004011A (is)
MY (1) MY130727A (is)
NO (1) NO20011933L (is)
NZ (1) NZ510275A (is)
OA (1) OA11664A (is)
PA (1) PA8484301A1 (is)
PE (1) PE20001286A1 (is)
PL (1) PL195789B1 (is)
PT (1) PT1123088E (is)
SK (1) SK286473B6 (is)
TR (1) TR200101103T2 (is)
TW (1) TW577756B (is)
UA (1) UA67802C2 (is)
UY (1) UY25765A1 (is)
WO (1) WO2000024383A1 (is)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295436A1 (de) * 1997-11-12 2011-03-16 Bayer Schering Pharma AG 2-Phenyl-substituierte Imidazotriazinone als Phosphodiesterase V Inhibitoren
DE69939748D1 (de) 1998-11-02 2008-11-27 Elan Pharma Int Ltd Multipartikuläre zusammensetzung von methylphenidat mit modifizierter freisetzung
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
AU8444401A (en) * 2000-09-06 2002-03-22 Tanabe Seiyaku Co Preparations for oral administration
WO2002036099A1 (en) 2000-10-30 2002-05-10 Euro-Celtique S.A. Controlled release hydrocodone formulations
KR100750554B1 (ko) * 2001-02-15 2007-08-20 다나베 세이야꾸 가부시키가이샤 구강 내 속붕괴성 정제
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
ITMI20020515A1 (it) * 2002-03-12 2003-09-12 Jagotec Ag Sistema per il rilasco controllato di uno o piu' principi attivi
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
AU2005239962B2 (en) 2004-05-11 2011-07-07 Eb Ip Lybrido B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
DE102004023069A1 (de) 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
GB0421121D0 (en) * 2004-09-22 2004-10-27 Natrocell Technologies Ltd Composite rodenticide
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
CA2613617A1 (en) * 2005-06-27 2007-01-04 Daniel Drai Compositions and methods for enhancement of sexual function
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
EP1931797A2 (en) * 2005-09-29 2008-06-18 Bayer HealthCare AG Pde inhibitors and combinations thereof for the treatment of urological disorders
EP1945214A1 (en) 2005-10-29 2008-07-23 Boehringer Ingelheim International GmbH Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP2037927B1 (en) 2006-06-30 2010-01-27 Boehringer Ingelheim International GmbH Flibanserin for the treatment of urinary incontinence and related diseases
BRPI0716439B8 (pt) 2006-08-14 2021-05-25 Boehringer Ingelheim Int sistemas de liberação farmacêutico compreendendo flibanserina, processo para preparação e uso dos mesmos
CN101505736A (zh) 2006-08-25 2009-08-12 贝林格尔.英格海姆国际有限公司 控制释放系统及其制造方法
EP1925307A1 (en) * 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
US20080226715A1 (en) * 2007-03-16 2008-09-18 Albert Cha Therapeutic compositions and methods
KR20100029762A (ko) * 2007-06-13 2010-03-17 바이엘 쉐링 파마 악티엔게젤샤프트 청력 장애 치료용 ｐｄｅ 억제제
UY31335A1 (es) 2007-09-12 2009-04-30 Tratamiento de sintomas vasomotores
US20110033506A1 (en) * 2008-02-08 2011-02-10 Adel Penhasi Combination dosage form of low-dose modafinil and low-dose sildenafil
MX339136B (es) * 2008-12-12 2016-05-13 Rhein Siegfried Sa De Cv Composicion de liberacion pulsatil de sildenafil y proceso para prepararla.
KR101004205B1 (ko) * 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
EA015250B9 (ru) * 2010-11-19 2013-10-30 Тева Фармасьютикал Индастриз, Лтд. Таблетка силденафила, обеспечивающая модифицированную фармакокинетику, и способ ее изготовления
MX353623B (es) 2011-05-13 2018-01-22 Eb Ip Hybritabs B V Sistema de suministro de farmaco.
WO2013016144A1 (en) * 2011-07-22 2013-01-31 Pom Wonderful, Llc Compositions comprising pomegranate polyphenols in combination with erectile dysfunction-treating compounds, and methods of treating erectile dysfunction therewith
WO2017168174A1 (en) * 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN113995727B (zh) * 2021-11-08 2023-04-07 山东鲁抗医药股份有限公司 一种5型磷酸二酯酶抑制剂片剂及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
JPS54119021A (en) * 1978-03-06 1979-09-14 Nippon Kayaku Co Ltd Carcinostatic agent
CH648754A5 (en) * 1979-08-16 1985-04-15 Ciba Geigy Ag Pharmaceutical slow release tablet
JPS5748908A (en) * 1980-09-08 1982-03-20 Kyorin Pharmaceut Co Ltd Prolonged release type nicomol pharmaceutical
FR2624732B1 (fr) 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
MC2025A1 (fr) * 1988-04-20 1990-04-25 Asta Pharma Ag Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee
IT1229856B (it) * 1989-04-20 1991-09-13 Recordati Chem Pharm Compresse a rilascio controllato contenenti flavossato.
US5474784A (en) 1990-03-02 1995-12-12 British Technology Group Limited Dispensing device
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
ES2149250T3 (es) * 1993-04-23 2000-11-01 Novartis Ag Dispositivo para la administracion de medicamentos con liberacion controlada.
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
AU2976897A (en) * 1996-06-18 1998-01-07 Otsuka Pharmaceutical Co., Ltd. Multiple-unit type prolonged action drug preparation
JPH1067657A (ja) * 1996-06-18 1998-03-10 Otsuka Pharmaceut Co Ltd マルチプルユニット型持続性製剤
CN1244119A (zh) * 1997-01-06 2000-02-09 辉瑞大药厂 迅速释放和掩蔽味觉的药物剂型
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6277884B1 (en) * 1998-06-01 2001-08-21 Nitromed, Inc. Treatment of sexual dysfunction with N-hydroxyguanidine compounds
DE69916627T2 (de) * 1998-09-04 2005-07-28 Ortho-Mcneil Pharmaceutical, Inc. 5-heterozyklyl-pyrazolo[4,3-d]pyrimidin-7-one für die behandlung von männlichen erectilen dysfunktionen

Also Published As

Publication number Publication date
AU5878799A (en) 2000-05-15
GT199900184A (es) 2001-04-14
CY1106239T1 (el) 2011-06-08
MXPA01004011A (es) 2003-03-10
JP2002528408A (ja) 2002-09-03
MA26700A1 (fr) 2004-12-20
DZ2923A1 (fr) 2004-03-01
DE69933383D1 (de) 2006-11-09
BG65323B1 (bg) 2008-02-29
DE69933383T2 (de) 2007-02-01
CZ20011427A3 (cs) 2001-10-17
MY130727A (en) 2007-07-31
HK1041818A1 (zh) 2002-07-26
PE20001286A1 (es) 2000-11-22
PA8484301A1 (es) 2000-09-29
NO20011933D0 (no) 2001-04-19
PL195789B1 (pl) 2007-10-31
EP1123088A1 (en) 2001-08-16
DK1123088T3 (da) 2007-01-02
NZ510275A (en) 2003-07-25
CA2348086A1 (en) 2000-05-04
SK5192001A3 (en) 2002-09-10
UA67802C2 (uk) 2004-07-15
US6964780B1 (en) 2005-11-15
OA11664A (en) 2005-01-07
ES2272082T3 (es) 2007-04-16
WO2000024383A1 (en) 2000-05-04
ATE340562T1 (de) 2006-10-15
PL347476A1 (en) 2002-04-08
ID28232A (id) 2001-05-10
EP1123088B1 (en) 2006-09-27
HUP0104318A3 (en) 2003-12-29
HUP0104318A2 (hu) 2002-03-28
HRP20010285A2 (en) 2002-06-30
UY25765A1 (es) 2001-08-27
EA004068B1 (ru) 2003-12-25
BR9914718A (pt) 2001-07-10
BG105465A (bg) 2001-12-29
PT1123088E (pt) 2007-01-31
IL141764A0 (en) 2002-03-10
KR20010075659A (ko) 2001-08-09
CA2348086C (en) 2007-01-23
AP2001002125A0 (en) 2001-04-04
EE200100235A (et) 2002-08-15
TW577756B (en) 2004-03-01
CR6326A (es) 2004-02-23
TR200101103T2 (tr) 2001-09-21
AU756509B2 (en) 2003-01-16
NO20011933L (no) 2001-06-25
CN1324233A (zh) 2001-11-28
CO5160262A1 (es) 2002-05-30
EA200100298A1 (ru) 2001-08-27
IL141764A (en) 2008-06-05
SK286473B6 (sk) 2008-11-06

Similar Documents

Publication Publication Date Title
IS5865A (is) Lyfjasamsetningar með stýrða losun sem innihalda CGMP PDE-5 lata
HUP0301114A3 (en) Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents and pharmaceutical compositions containing them
IS6304A (is) Kínasólínefnasambönd og lyfjafræðilegar efnasamsetningar sem innihalda þau
HUP0200355A3 (en) 4-aminopyrrolopyrimidines as kinase inhibitors, pharmaceutical compositions containing them and their use
IL158079A0 (en) Pharmaceutical compositions containing an interleukin-6 antagonist
MA24878A1 (fr) Compositions de parfum
HUP0401950A3 (en) Pyrimidine derivatives and pharmaceutical compositions containing that compounds
PL369404A1 (en) Impact-resistant polyolefin compositions
HUP0400641A3 (en) Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
IL151530A0 (en) Compositions containing alpha-2-adrenergic agonist components
IS7077A (is) Kristölluð samsetning sem inniheldur essítalópram
IL150447A0 (en) Pharmaceutical compositions containing entecavir
HUP0401333A3 (en) Spiropyrazole compounds and pharmaceutical compositions containing them
DE69942465D1 (de) Antiparasitäre Zusammensetzungen
IS7178A (is) Skynmatshæfar samsetningar sem leysast upp í munni
IL161430A0 (en) Pharmaceutical compositions containing ecteinascidin 743
EP1423122A4 (en) COMPOSITIONS AND METHODS RELATED TO NEW BENZODIAZEPINE COMPOUNDS AND THEIR OBJECTIVES
HUP0400077A2 (hu) Deutériumozott 3-piperidino-propiofenon és a vegyületeket tartalmazó gyógyszerekészítmények
GB9927315D0 (en) Inhibitor compositions
GB2370841B (en) High solid paint compositions
HUP0103382A2 (en) Naaladase inhibitors useful as pharmaceutical compounds and compositions
HUP0400654A3 (en) Substituted 8-arylquinoline phosphodiesterase 4 inhibitors and pharmaceutical compositions containing them
GB0129489D0 (en) Sustained-release compositions
DE69918180D1 (de) Kathodische elektrotauchlackzusammensetzung
EP1311638A4 (en) COATING COMPOSITIONS